




A blurred background image showing students in a classroom. In the foreground, a person's hands are visible, holding a red pen and writing on a piece of paper. Other students and papers are visible in the background, creating a sense of a busy learning environment.

# 112 年度國考複習

腎臟科 CR 巴重翰



學BAR



<https://www.learningbar.tw/>

阿摩線上測驗



阿摩線上測驗

<https://yamol.tw/main.php>



# 醫師國考出題統計

- 約**5-6題? 連外科都出!** 都是考**臨床題**
- 是得分的重要部分
- 太難的就算了，反正大家都在猜
- 就算不會，猜大部分也猜的到！

By 蔡尚峰醫師



# 必拿考題!!!

- 酸鹼診斷判斷
- 鉀離子(低-診斷 ; 高-診斷、處置)
- CKD-AKI

## 聯想、關鍵字(疾病)!!!

	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	Total
第一篇 腎臟內科	9	20	16	16	18	15	18	14	12	16	12	16	19	8	2	211
甲、酸鹼平衡			1	2	2	1	3	1	1	2	1	5	3			22
乙、離子平衡	3	6	1	2	2	5	9	6	5	5	6	3	2	3	1	59
丙、急性腎損傷		5	1	4	6	1	1	2	1	2		1	6			30
丁、腎臟疾病各論	1	3	5	4	6	2	3	3	1	4	3	3	3			41
戊、慢性腎臟病	2	1		2	2	5	1		2	1		1	4	3		24
己、透析治療	3	1	4	2				1	2	1	1	1				16
庚、腎臟移植		1	1								1		1	2	1	7
辛、多囊性腎病		3	3			1	1	1		1		2				12

111-1-4

某位70歲女性因為喝有機磷

( organophosphate ) 農藥自殺而被送來醫院急救。當農藥毒性發作時，最不可能導致下列何種徵象？

A.肌肉無力

B.口水、淚液減少

C.癲癇發作 ( seizure )

D.腹瀉、大便失禁

有機磷中毒的症狀



111-1-5

承上題，針對上述病人之治療，下列何種方式最不適當？

A.服用活性碳

B.注射atropine

C.注射physostigmine

D.注射pralidoxime ( 2-PAM )

有機磷中毒的處置



111-1-23

53歲男性腎臟移植病人，移植腎功能惡化，1個月內serum creatinine 由1.0 mg/dL，上升至2.0 mg/dL，移植腎切片顯示內皮細胞損傷（endothelial injury）、C4d 沉積，下列何種治療最不適當？

A.血漿置換（plasmapheresis）

B.免疫球蛋白注射（immunoglobulin infusion）

C.anti-IL2 接受器（anti-IL2 receptor）單株抗體注射

D.anti-CD20 單株抗體（rituximab）注射

## 腎移植急性排斥的處置

AMR or ACR?





111-1-25

一名50歲男性尿路結石病人的尿液檢查發現結晶物質如附圖所示，下列何項建議最為適當？

- A.consume a low-calcium diet from now on
- B.need not modulate urine pH**
- C.start taking tiopronin or penicillamine
- D.supply high-dose vitamin C

## 腎結石種類與鏡檢

Urine routine 判讀

尿液酸鹼？

Radiolucent/opaque？



111-1-26

下列何項不是急性間質性腎炎 ( acute interstitial nephritis ) 的常見臨床表現？

- A. 尿液分析僅輕度蛋白尿 (  $< 1.0$  g/24 hours ) 和血尿
- B. 血清肌酸酐上升合併鈉排出率 ( fractional excretion of sodium )  $> 1.0$
- C. 使用氫離子幫浦阻斷劑後發生腎病症候群程度的蛋白尿 ( nephrotic-range proteinuria )
- D. 腎衰竭發展耗時數日至數週，符合原發性免疫反應動力學 ( kinetics )

## Nephritis的臨床表現

Nephrotic/nephritis的定義？

侵犯Interstitial/glomerular的表現



111-1-27

有關多囊性腎臟病的敘述，下列何者錯誤？

- A. 自體顯性多囊性腎臟病（autosomal dominant polycystic kidney disease, ADPKD）是最常見的遺傳性腎臟疾病
- B. 自體顯性多囊性腎臟病（autosomal dominant polycystic kidney disease, ADPKD）的致病基因目前已知的有兩型：第一型：PKD1 基因，位在第16對染色體短臂上（16p13.3）；第二型：PKD2 基因，位在第4對染色體長臂上（4q21-q23）
- C. 多囊性腎臟病的患者，約3.2%~10%會發生腦部動脈瘤，男性有較高的盛行率，特別是年紀小於30歲者
- D. 多囊性腎臟病的患者與一般末期腎病不同的是，患者發生嚴重貧血的機率較小，當惡化至尿毒症時，患者一樣可接受透析治療或腎臟移植

## 多囊腎

ADPKD/ATPKD

AD, 基因型, 年齡, 併發多囊肝  
症狀, 感染之處置



111-1-28

下列原發性腎病變引起的腎病症候群（nephrotic syndrome），那一種最容易發生血栓併發症（如：renal vein thrombosis、pulmonary embolism和deep-vein thrombosis）？

A.type I membranoproliferative glomerulonephritis（MPGN）

B.focal segmental glomerulosclerosis（FSGS）

C.membranous nephropathy（MN）

D.minimal change disease（MCD）

## Nephrotic syndrome

各GN類型；凝血因子製造增加

成人,小孩,Lupus nephritis, 感染後(IgA)



111-1-29

在皮質集尿管 ( cortical collecting duct ) 有三種上皮細胞，下列敘述何者正確？

- A. 主細胞 ( principal cells ) 是負責鉀離子的再吸收細胞
- B. 作用在主細胞 ( principal cells ) 包括：醛固酮，K<sup>+</sup> - sparing利尿劑及醛固酮拮抗劑
- C. A型間細胞 ( type A intercalated cells ) 控制酸的再吸收與重碳酸根分泌
- D. B型間細胞 ( type B intercalated cells ) 控制酸的分泌與重碳酸根再吸收

腎小管各段功能  
(太專了...)



111-1-30

關於急性腎損傷處置的敘述，下列何者錯誤？

A.對於非出血性休克病人的靜脈輸液，建議使用等張晶體溶液 ( isotonic crystalloid solution )

**B.建議重症病人以低蛋白飲食來延緩透析**

C.在體液容積足夠的情況下，furosemide stress test能夠作為急性腎損傷惡化的預測工具

D.不建議使用低劑量多巴胺 ( dopamine ) 來預防急性腎損傷

## AKI處置

AKI的分類與原因 (pre/post/intrinsic)

AKI/CKD異同



111-2-1

病人主訴頻尿，每次尿量都很多，並未使用利尿劑。收集 24 小時尿液檢查結果：總尿量 3500 mL/day，urine osmolality 450 mosmol/L。病人的檢查數值，最符合下列那一種多尿症的診斷？

A. 溶質性利尿 ( solute diuresis )

B. 原發性多飲症 ( primary polydipsia )

C. 中樞性尿崩症 ( central diabetes insipidus )

D. 腎源性尿崩症 ( nephrogenic diabetes insipidus )

## Polyuria的鑑別診斷

Osmolality, hypernatremia等判斷



111-2-2

關於懷孕期間慢性高血壓的治療建議，下列何者最不適當？

- A. 首選藥物為血管收縮素轉化酶抑制劑 ( angiotensin-converting enzyme inhibitor ) 或血管收縮素受體阻斷劑 ( angiotensin receptor blocker )
- B. 可以使用 labetalol 或 nifedipine 控制血壓
- C. 尚無足夠證據證實輕微高血壓的治療能改善懷孕預後
- D. 收縮壓目標控制在 130 ~ 150 mmHg，而舒張壓目標控制在 80 ~ 100 mmHg

**懷孕期間高血壓用藥選擇**

**切記不可用**

**ACEI/ARB inhibitor!!!**

ASSED



111-2-25

下列何項不是馬兜鈴酸腎病變（ aristolochic acid nephropathy ）的臨床特徵？

- A.marked protein-energy malnutrition
- B.rapid progression to renal failure
- C.upper urinary tract urothelial cancer
- D.disproportionate anemia

**表面上說馬兜鈴腎病變  
實際上考AKI症狀與處置!!!**



111-2-26

一名 60 歲女性，3 小時前開始左腰疼痛並出現血尿，體溫 38.3°C，靜脈腎盂攝影檢查 10 分鐘前、後呈像如附圖左、右。下列何項治療處置應最優先考慮？

- A. 給與 $\alpha$ 1腎上腺素受體阻斷劑
- B. 照會泌尿科醫師尋求介入治療
- C. 投與經驗性抗生素並追蹤培養結果
- D. 開立止痛藥並鼓勵大量喝水

**AKI應先排除post renal**  
**Post renal的鑑別診斷與處置**  
**一根shelly還是一根Foley?**

111-2-28

有關 focal segmental glomerulosclerosis  
何者錯誤?

A.FSGS 以血尿、高血壓、各種程度的蛋白尿及腎功能不全表現的風險會進入透析治療

B.病理報告應包括在 corticomedullary junction disease (MCD)

C.病理報告 collapsing type FSGS with segmental or global glomerular

D.治療續發性的 FSGS，不需使用類固醇

各類GN的病理表現與治療



111-2-29

下列那一段腎小管 ( renal tubule ) 可透過抗利尿荷爾蒙 ( antidiuretic hormone, ADH ) 的作用增加對水分的通透性？

A.近端腎小管 ( proximal tubule )

B.Henle 氏環下行枝 ( descending limb of Henle's loop )

C.遠端腎小管 ( distal convoluted tubule )

D.集尿管 ( collecting duct )

**ADH作用在後段腎小管  
各段腎小管之功能？**



111-2-30

一位 50 歲男性因懷疑腎結石接受 intravenous urography ( IVU ) 檢查，第 3 天發現 BUN 由 30 mg/dL 升至 70 mg/dL，血中 creatinine 由 1.5 mg/dL 升至 4.5 mg/dL。下列有關顯影劑與腎病變的敘述，何者正確？

- A. 顯影劑可經過 reactive oxygen species 之機轉，直接傷害腎絲球
- B. 血中 creatinine 通常在 10~14 天達高峰，於 2~3 週後開始恢復
- C. 顯影劑之種類、劑量與腎損傷之嚴重程度無關
- D. 病人若有 multiple myeloma 或既有的腎臟疾病，較容易發生此併發症

## Contrast-medium nephropathy 與AKI

MM會讓血液黏稠

Acid-Base Disturbances

Sodium and Water Homeostasis

Potassium Homeostasis

Renal Failure/ other electrolyte

Glomerular Disease

Urinalysis

Nephrolithiasis



# Acid-Base Disturbances

Gas 判断:

**Acid-Base** → **Compensate**

**Diuretic- BG syndrome**

**Etiology- Rx**



## 必記數字!

---

pH **7.4**,  $\text{CO}_2$  **40**,  $\text{HCO}_3^-$  **24**,

$\text{AG} = [\text{Alb}] * 2.5$ ,  $\Delta \text{AG} / \Delta \text{HCO}_3^- = 1 \sim 2$

UAG (-), osm G: 10

## Acidemia vs. acidosis

---

**pH絕對值:** ex.  $\text{pH} < 7.35 = \text{acidemia}$

**-osis:** 預測值相比較，身體處理過程





# primary vs. secondary disorder

Primary Disorders				
pH	HCO <sub>3</sub>	P <sub>a</sub> CO <sub>2</sub>	Primary Disorder	Problem
↓	↓↓	↓	Metabolic acidosis	Gain of H <sup>+</sup> or loss of HCO <sub>3</sub>
↑	↑↑	↑	Metabolic alkalosis	Gain of HCO <sub>3</sub> or loss of H <sup>+</sup>
↓	↑	↑↑	Respiratory acidosis	Hypoventilation
↑	↓	↓↓	Respiratory alkalosis	Hyperventilation



primary

Metabolic

Respiratory

secondary

身體代償會使HCO<sub>3</sub><sup>-</sup>, CO<sub>2</sub> 同方向



# 106-01

• 一位病人血液氣體分析顯示pH 7.51，  
PaCO<sub>2</sub> 49 mmHg，HCO<sub>3</sub><sup>-</sup> 38 mmol/L，  
下列何者正確？

- A.代謝性酸中毒(酸血症)
- **B.代謝性鹼中毒**
- C.呼吸性酸中毒
- D.呼吸性鹼中毒



# Compensation?

Compensation for Acid/Base Disorders (NEJM 2014;371:1434)	
Primary Disorder	Expected Compensation
Metabolic acidosis	$\downarrow P_aCO_2 = 1.2 \times \Delta HCO_3$ or $P_aCO_2 = (1.5 \times HCO_3) + 8 \pm 2$ (Winters' formula) (also, $P_aCO_2 \approx$ last 2 digits of pH)
Metabolic alkalosis	$\uparrow P_aCO_2 = 0.7 \times \Delta HCO_3$ or $P_aCO_2 = 0.7 (HCO_3 - 24) + 40 \pm 2$ or $HCO_3 + 15$
Acute respiratory acidosis	$\uparrow HCO_3 = 0.1 \times \Delta P_aCO_2$ (also, $\downarrow pH = 0.008 \times \Delta P_aCO_2$ )
Chronic respiratory acidosis	$\uparrow HCO_3 = 0.35 \times \Delta P_aCO_2$ (also, $\downarrow pH = 0.003 \times \Delta P_aCO_2$ )
Acute respiratory alkalosis	$\downarrow HCO_3 = 0.2 \times \Delta P_aCO_2$ (also, $\uparrow pH = 0.008 \times \Delta P_aCO_2$ )
Chronic respiratory alkalosis	$\downarrow HCO_3 = 0.4 \times \Delta P_aCO_2$

1.25

0.75

1


4

2

4

# Metabolic acidosis


**AG** →  $\Delta/\Delta$  → **KILR or OG**



**NAG** → **GI, (NEP → UAG)**



# Acid-Base Disturbances/ Sodium and Water Homeostasis/ Potassium Homeostasis/



- AG 異常時，可以推測以下疾病。

AG	UC (無法測定的陽離子)	UA (無法測定的陰離子)
↑ > 12 增加	↓ hypogammaglobulinemia 低鉀、低鈣、低鎂	↑ MUDPILES (見後述)
↓ < 12 減少	↑ hypergammaglobulinemia 高鉀、高鈣、高鎂、鋰中毒	↓ 低白蛋白血症



95-21 下列何者**不會**造成血清低離子間隙 (low anion gap) ?

1. 鋰鹽中毒 (Lithium intoxication)
2. 腎病症候群 (Nephrotic syndrome)
- 3. 高血磷症 (Hyperphosphatemia)**
4. 高血脂 (Hyperlipidemia)


low anion gap: UA↓ or UC↑ (Li, )

4. lab error due to hyperlipidemia (Spurious Hyperchloremia and Decreased Anion Gap in Hyperlipidemia)




Figure 6. Gamblegram


MARCH 25, 2018 By  
MATTHEW WATTO, MD





**Non-gap acidosis**



**Anion gap acidosis**



**Gamblegram**



# High anion gap ID: 1940104


K

I

L

R

Etiologies of AG Metabolic Acidosis	
<b>Ketoacidosis</b>	<b>Diabetes mellitus</b> , alcoholism, starvation ( <i>NEJM</i> 2014;372:546)
<b>Ingestions</b>	<p><b>Methanol</b> (windshield fluid, antifreeze, solvents, fuel): metab to formic acid</p> <p><b>Ethylene glycol</b> (antifreeze): metab to glycolic and oxalic acids</p> <p><b>Propylene glycol</b> (pharmaceutical solvent, eg, IV diazepam, lorazepam, and phenobarbital; antifreeze): lactic acidosis</p> <p><b>Salicylates</b>: metabolic acidosis (from lactate, ketones) + respiratory alkalosis due to stimulation of CNS respiratory center</p> <p><b>Glutathione depletion</b>: acetaminophen → ↑ endogenous organic acid 5-oxoproline in susceptible hosts (malnourished, female, renal failure)</p>
<b>Lactic acidosis</b> ( <i>NEJM</i> 2014; 371:2309)	<p><b>Type A</b>: impairment in tissue oxygenation eg, <b>circulatory or respiratory failure, sepsis</b>, ischemic bowel, carbon monoxide, cyanide</p> <p><b>Type B</b>: no impairment in tissue oxygenation. ↓ clearance (eg, hepatic dysfxn) or ↑ generation [eg, malig, EtOH, thiamine def., meds (metformin, NRTIs, salicylates, propylene glycol, propofol, isoniazid, linezolid)]</p> <p><b>D-lactic acidosis</b>: short bowel syndrome → precip by glc ingest → metab by colonic bacteria to D-lactate; not detected by standard lactate assay</p>
<b>Renal failure</b>	Accumulation of organic anions such as phosphates, sulfates, urate, etc.





# High anion gap- high osmolal gap

- Osmolal gap (OG)** = measured osmoles – calculated osmoles  
 calculated osmoles =  $(2 \times \text{Na}) + (\text{glucose}/18) + (\text{BUN}/2.8)$   
 (can +  $[\text{EtOH}/4.6]$  if have EtOH level and want to test if other ingestions)  
 OG >10 → suggests ingestion (see below) but lacks specificity (can be elevated in lactic acidosis, DKA, and alcoholic ketoacidosis)  
 for methanol/ethylene glycol: early on, OG precedes AG; later OG may be nl with ⊕ AG

Ingestions (NEJM 2018;378:270) Call poison control for guidance (800-222-1222)			
AG	OG	Ingestion	Other Manifestations
↑	nl	Acetaminophen	Hepatitis
		Salicylates	Fever, tachycardia, tinnitus; met. acid. + resp. alkalosis
↑	↑	Methanol	ΔMS, blurred vision, pupillary dilation, papilledema
		Ethylene glycol	ΔMS, cardiopulm. failure, hypoCa. <b>Ca oxalate crystals</b> → AKI. Urine fluoresces under UV light.
		Propylene glycol	AKI, liver injury
		Diethylene glycol	AKI, N/V, pancreatitis, neuropathy, lactic acidosis
nl/↑	↑	Isopropyl alcohol	ΔMS, fruity breath (acetone), pancreatitis, lactic acidosis
		Ethanol	Alcoholic fetor, ΔMS, hepatitis; keto + lactic acidosis ± met. alk. (vomiting)

104-19

下列何者不是高陰離子間隙代謝性酸中毒(high-anion-gap metabolic acidosis )的原因?


- A. lactic acidosis
- B. ketoacidosis
- **C. diarrhea**
- D. salicylate intoxication

(叫不出酸的名字的！)




# Three buckets of Non gap metabolic acidosis


給 Cl



漏  $\text{HCO}_3^-$



漏  $\text{HCO}_3^-$



## Chloride intoxication

Dilutional acidosis

HCl intoxication

Chloride gas intoxication

Early renal failure

## GI loss of $\text{HCO}_3^-$

Diarrhea

Surgical drains

Fistulas

Ureterosigmoidostomy

Obstructed  
ureteroileostomy

Cholestyramine

## Renal loss of $\text{HCO}_3^-$

Renal tubular acidosis

Proximal

Distal

Hypoaldosteronism



# normal anion gap: GI, NEP

Etiologies of Non-AG Metabolic Acidosis	
<b>GI losses of <math>\text{HCO}_3</math></b>	Diarrhea, intestinal or pancreatic fistulas or drainage
<b>RTAs</b>	<i>See section on renal tubular acidoses below</i>
<b>Early renal failure</b>	Impaired generation of ammonia
<b>Ingestions</b>	Acetazolamide, sevelamer, cholestyramine, toluene
<b>Dilutional</b>	Due to rapid infusion of bicarbonate-free IV fluids
<b>Posthypocapnia</b>	Respiratory alkalosis → renal wasting of $\text{HCO}_3$ ; rapid correction of resp. alk. → transient acidosis until $\text{HCO}_3$ regenerated
<b>Ureteral diversion</b>	Colonic $\text{Cl}^-/\text{HCO}_3^-$ exchange, ammonium reabsorption

# Urine anion gap= Urine: Na+K-Cl


- 腎排酸是以 $\text{NH}_3 + \text{H}^+ = \text{NH}_4^+$ 來排出
- Urine:  $u\text{Na} + u\text{K} + \text{未測cation} = u\text{Cl} + u\text{HCO}_3^- + \text{未測得anion}$
- $\text{UAG} = \text{未測得anion} - \text{未測cation} = u\text{Na} + u\text{K} - u\text{Cl}$
- 若腎功能好的，處於metabolic acidosis時，應該要排酸，故urine中 $\text{NH}_4^+$ 應該是上升的
- 而 $\text{NH}_4^+$ 屬於未測得cation，故 $\text{UAG} < 0$



# Urinary anion gap Gamblegram

metabolic acidosis

$$\text{UAG} = \text{uNa} + \text{uK} - \text{uCl} < 0$$



cations = anions

**PASSED**

Acid-Base Disturbances/ Sodium and Water Homeostasis/ Potassium Homeostasis/

AG

AG


KILR

UAG




OG

GI

NEP



# RTA (UAG > 0)



**FIGURE 21-1** The nephron, depicting its location, segments, and the sites of action of different classes of diuretics.



**Proximal** (Type II): ↓ proximal reabsorption of  $\text{HCO}_3^-$

**1° (Fanconi's syndrome)** = ↓ proximal reabsorption of  $\text{HCO}_3^-$ ,  $\text{PO}_4$ , glc, amino acids

**Acquired: paraprotein** (MM, amyloidosis), metals (Pb, Cd, Hg, Cu), ↓ vit D, PNH, renal Tx

**Meds:** acetazolamide, aminoglycosides, ifosfamide, cisplatin, topiramate, tenofovir

**Distal** (Type I): defective distal  $\text{H}^+$  secretion

**1°, autoimmune (Sjögren's, RA, SLE)**, hypercalciuria, meds (ampho, Li, ifosfamide); normally a/w ↓ K; if **with ↑ K sickle cell, obstruction, renal transplant**



**Hypoaldo** (Type IV): hypoaldo  $\rightarrow$   $\uparrow$  K  $\rightarrow$   $\downarrow$  NH<sub>3</sub> synthesis  $\rightarrow$   $\downarrow$  urine acid-carrying capacity

$\downarrow$  **renin: diabetic nephropathy**, NSAIDs, chronic interstitial nephritis, calcineurin inh, HIV

$\downarrow$  **aldo production**: 1° AI, ACEI/ARBs, heparin, severe illness, inherited ( $\downarrow$  21-hydroxylase)

$\downarrow$  **response to aldosterone**

meds: **K-sparing diuretics**, **TMP-SMX**, pentamidine, calcineurin inhibitors  
tubulointerstitial disease: sickle cell, SLE, amyloid, DM



# 酸鹼情境

## High AG:

DM(DKA, metformin)

誤食OOXX

sepsis, shock

Late renal failure

## Non-AG: GI (吐拉), NEP

DM: type 4 RTA

Autoimmune: type 2 RTA (RA, SLE, SS)

Early renal failure



Renal Tubular Acidosis								
Location	Type	Acidosis	UAG	HCO <sub>3</sub> <sup>-</sup>	UpH	FE <sub>HCO<sub>3</sub></sub> <sup>b</sup>	K	Complications
Proximal	II	Moderate	±	12-20	<5.3 <sup>a</sup>	>15%	↓	Osteomalacia
Distal	I	Severe	⊕	<10	>5.3	<3%	↓ <sup>c</sup>	Kidney stones
Hypoaldo	IV	Mild	⊕	>17	<5.3	<3%	↑	Hyperkalemia

**Treatment of severe metabolic acidoses (pH <7.2)** (*Nat Rev Nephrol* 2012;8:589)

- DKA: insulin, IVF, K repletion (*NEJM* 2015;372:546); AKA: dextrose, IVF, replete K, Mg, PO<sub>4</sub>
- Lactic acidosis: treat underlying condition, avoid vasoconstrictors, avoid “Type B” meds
- Renal failure: hemodialysis
- Methanol & ethylene glycol: fomepizole (20 mg/dL), vit. B<sub>1</sub> & B<sub>6</sub>

} underlying

(ethylene glycol), folate (methanol), dialysis (if AKI, VS unstable, vision Δ or >50 mg/dL) (*NEJM* 2018;378:270)

- Alkali therapy: if pH <7.1 or <7.2 and co-existing AKI (*Lancet* 2018;392:21)
- NaHCO<sub>3</sub>: amps by IV push or infusion of three 50-mmol amps in 1 L D<sub>5</sub>W if less urgent  
 can estimate mmol of HCO<sub>3</sub> needed as [desired-current HCO<sub>3</sub>]<sub>serum</sub> × wt (kg) × 0.4  
 side effects: ↑ volume, ↑ Na, ↓ ICa, ↑ P<sub>a</sub>CO<sub>2</sub> (& ∴ intracellular acidosis; ∴ *must ensure adequate ventilation* to blow off CO<sub>2</sub>)



22. 56歲男性**糖尿病**人因胸部不適至急診，初步檢查血中 creatinine 2.0 mg/dL、**K<sup>+</sup> 5.8** mEq/L、Na<sup>+</sup> 139 mEq/L、Cl<sup>-</sup> 116 mEq/L、HCO<sub>3</sub><sup>-</sup> 18 mEq/L、osmolality 290 mOsm/kg·H<sub>2</sub>O、尿中 creatinine 12 mg/dL、K 9.6 mEq/dL、osmolality 580 mOsm/kg·H<sub>2</sub>O，病人最可能的**診斷**是

- A. 第二型腎小管酸血症(type 2 renal tubular acidosis )
- B. metformin 引發酸血症(metformin related acidosis )
- C. 低腎素低醛固酮血症(hyporeninemic hypoaldosteronism)**
- D. 糖尿病酮酸血症(diabetic ketoacidosis )

AG 139-116-18=5



95-10 一酗酒病患因意識不清，劇烈嘔吐被送至急診室。其血液生化檢查及動脈血分析如下：  
**pH: 7.40, PaCO<sub>2</sub>: 40 mmHg, HCO<sub>3</sub><sup>-</sup>: 24 mEq/L,**  
Glucose: 120 mg/dL, BUN: 10 mg/dL, Cr: 0.7 mg/dL, **Na: 134 mEq/L, K: 2.6 mEq/L, Cl: 80 mEq/L,** Acetone: 3+。則 (100-4數字完全一樣又考一次)

下列敘述何者正確？

1. 病患血液酸鹼值正常無代謝性酸鹼疾病
- 2. 病患患有代謝性酸中毒合併代謝性鹼中毒**
3. 病患患有代謝性酸中毒合併呼吸性鹼中毒
4. 病患患有代謝性鹼中毒合併呼吸性酸中



102-26

下列那一個病例較符合所列之動脈血氣體分析和血清電解質的檢查結果？ **pH 7.32**， **PaO<sub>2</sub> 110 mmHg**， **PaCO<sub>2</sub> 30 mmHg**， **HCO<sub>3</sub><sup>-</sup> 18 mEq/L**； **Na<sup>+</sup> 138**， **K<sup>+</sup> 3.5**， **Cl<sup>-</sup> 97**(電解質的單位是 mmol/L )

A. 70 歲病人因便秘嚴重，服用 magnesium sulfate 導致**腹瀉**數天

B. 28歲病人診斷為**修格連氏症候群**( Sjögren's syndrome )，無意間發現腎鈣化( nephrocalcinosis )，尿液酸鹼值為 6.5；給予 NH<sub>4</sub>Cl( 0.1 g/kg體重 )後，尿液酸鹼值為 6.0

**C. 20 歲病人第一型糖尿病病史 5 年，血糖控制不佳，最近因為期末考胰島素注射次數減少**

D. 60 歲病人因膽道阻塞放置**引流管引流膽汁**

AG=138-97-18=23>12



100-29

下列那一種是陰離子隙增加之代謝性酸中毒 (high anion gap metabolic acidosis) ?

1. 腹瀉(diarrhea)

**2. 飢餓 (starvation)**

3. 嘔吐( vomiting )

4. 輸尿管 - 乙形結腸造口術後  
( ureterosigmoidostomy )

**產生ketone (並無loss or gain)**






# Metabolic alkalosis


20  
or  
25

Etiologies of Metabolic Alkalosis	
<b>Saline responsive</b> UCI < 25 <b>Remote diuretic</b>	<b>GI loss of H<sup>+</sup>:</b> emesis, NGT suction, villous adenoma, chloridorrhea <b>Renal loss:</b> loop/thiazide, ↓ Cl intake, milk-alkali, Pendred syndrome Posthypercapnia, sweat losses in cystic fibrosis
<b>Saline resistant</b> UCI >40 <b>endocrine</b>	<b>Hypertensive (mineralocorticoid excess)</b> 1° hyperaldosteronism (eg, Conn's) 2° hyperaldosteronism (eg, renovascular dis., renin-secreting tumor) Non-aldo (Cushing's, Liddle's, exogenous mineralocorticoids, licorice) <b>Normotensive</b> Severe hypokalemia (K<2); exogenous alkali load (w/ AKI or ↓ vol) Bartter's syndrome (loop-like); Gitelman's syndrome (thiazide-like)


# Metabolic alkalosis

用**UCI**來看ECF volume的量！ ∴ urine  $\text{HCO}_3^-$ 會把UNa拉出來故不準！






# Diuretic- acid base



Brody's Human Pharmacology: Molecular to Clinical,  
5th Edition: ch 21

**FIGURE 21-1** The nephron, depicting its location, segments, and the sites of action of different classes of diuretics.



# Diuretic- [Na<sup>+</sup>]








Brody's Human Pharmacology: Molecular to Clinical,  
5th Edition: ch 21

**FIGURE 21-1** The nephron, depicting its location, segments, and the sites of action of different classes of diuretics.

# Diuretic- [K<sup>+</sup>] [Mg<sup>2+</sup>]










Site of diuretic action			
	Carbonic anhydrase inhibitors		Thiazide diuretics
	Osmotic diuretics		K <sup>+</sup> -sparing diuretics
	Loop diuretics		

Brody's Human Pharmacology: Molecular to Clinical, 5th Edition: ch 21

**FIGURE 21-1** The nephron, depicting its location, segments, and the sites of action of different classes of diuretics.

# Diuretic- [Ca<sup>2+</sup>]




Site of diuretic action			
	Carbonic anhydrase inhibitors		Thiazide diuretics
	Osmotic diuretics		K <sup>+</sup> -sparing diuretics
	Loop diuretics		

Brody's Human Pharmacology: Molecular to Clinical, 5th Edition: ch 21

**FIGURE 21-1** The nephron, depicting its location, segments, and the sites of action of different classes of diuretics.

# Diuretic- BG syndrome



Brody's Human Pharmacology: Molecular to Clinical, 5th Edition: ch 21

**FIGURE 21-1** The nephron, depicting its location, segments, and the sites of action of different classes of diuretics.



**Acid-Base Disturbances/** Sodium and Water Homeostasis/ Potassium Homeostasis/

	<b>B</b> arters	<b>G</b> itelman
位置	Thick ascending loop	Distal collecting duct
Transporter	Na-K-2Cl (NKCC2)	Na-Cl (NCC)
Medication analogue	Lasix (loop)	Thiazide
K	低血鉀	
Ca	Uca $\uparrow$ $\rightarrow$ 血 Ca $\downarrow$ ∴ 高血鈣要用 lasix	Uca $\downarrow$ $\rightarrow$ 血 Ca $\uparrow$ ∴ 降結石用 thiazide
Mg	UMg $\uparrow$	UMg $\uparrow$

64. 下列那一個病例**不符合**所列之動脈血氣體分析和血清電解質的檢查結果 [ pH 7.49 , PaO<sub>2</sub> 90 mmHg , PaCO<sub>2</sub> 43 mmHg , HCO<sub>3</sub><sup>-</sup> 28 ; Na<sup>+</sup> 139 , K<sup>+</sup> 3.0 , Cl<sup>-</sup> 89 ( 電解質的單位是mmol/L ) ] ?

(A) 甲：40歲女病人，最近半年發現高血壓；病人有時會下肢無力，血漿皮質醛固酮濃度為38 ng/dL ( 正常為10 ~ 25 )

**(B) 乙：37歲女病人，患有Sjögren's syndrome，腎臟超音波發現兩側腎臟的腎盂有鈣化跡象**

(C) 丙：30歲男病人因急性胰臟炎住院，給予鼻胃管引流，每天約引流出3000 mL

(D) 丁：22歲女病人長期服用thiazide diuretics減肥

**PASSED**

65. 【題組】 65.承上題，檢查該病人尿液，發現氯離子濃度為 $10 \text{ mmol/L}$ 。何者最為符合此結果？

(A)甲病人

(B)乙病人

**(C)丙病人**

(D)丁病人



31 下列那一個病例不符合所列之動脈血氣體分析和血清電解質的檢查結果？ pH 7.49， PaO<sub>2</sub> 90 mmHg， PaCO<sub>2</sub> 48 mmHg， HCO<sub>3</sub> 32 mEq/L； Na<sup>+</sup> 140， K<sup>+</sup> 2.7， Cl<sup>-</sup> 92（電解質的單位是 mmol/L）

A. 40歲甲病人，血壓 160/108 mmHg，血漿腎素活性 0.12 ng/mL/hr（正常值 1.0-3.5 ng/mL/hr）

B. 20歲乙女性，使用利尿劑 (hydrochlorothiazide) 減重

C. 40歲丙病人，血壓 162/102 mmHg，長期食用甘草（licorice）

**D. 60歲丁病人使用 acetazolamide 治療青光眼**



100-26 下列選項何者不是 Gitelman's syndrome 的特徵？

1. 低血鉀
2. 代謝性鹼中毒
3. 低血鎂
4. 高尿鈣



# Respiratory acidosis

Etiologies (also see “Hypercapnia”;  $PaCO_2 = VCO_2/VE(1-VD/VT)$ ;  $VE=RR \times VT$ )

產 $CO_2$ 酸、CNS到呼吸道、周邊肌肉

**CO<sub>2</sub> production** ( $\uparrow VCO_2$ ): fever, thyrotoxicosis, sepsis, steroids, overfeeding

**CNS depression:** sedatives (opiates, benzos, etc.), CNS trauma, central sleep apnea, obesity, hypoventilation, hypothyroidism

**Neuromuscular:** Guillain-Barré, poliomyelitis, ALS, MS, paralytics, myasthenia gravis, muscular dystrophy, severe  $\downarrow P$  &  $K$ , spinal cord injury



**CHE review**



# Respiratory alkalosis

**Hypoxia** → hyperventilation: pneumonia, CHF, PE, restrictive lung disease, anemia

## Primary hyperventilation

CNS stimulation, pain, anxiety, trauma, stroke, CNS infection, pontine tumors

**drugs:** salicylates toxicity (early),  $\beta$ -agonists, progesterone, methylxanthines, nicotine, pregnancy, sepsis, hepatic failure, hyperthyroidism, fever

**Pseudorespiratory alkalosis:** ↓ perfusion w/ preserved ventilation (eg, CPR, severe HoTN) → ↓ delivery of CO<sub>2</sub> to lungs for excretion; low PaCO<sub>2</sub> but ↑ tissue CO<sub>2</sub>



2. 下列那一種藥物或狀況最不可能造成呼吸性鹼中毒？

A. 水楊酸鹽(salicylates )

B. 高山

C. 懷孕

**D. 嗎啡(morphine )**





# Sodium and Water Homeostasis

低鈉鑑別診斷、對應治療

高鈉鑑別診斷(尿崩)、對應治療

Overcorrection- complication



Hyponatremia是指濃度低

Excess H<sub>2</sub>O relative to Na, usually due to ↑ ADH

就是這麼簡單

[Na<sup>+</sup>]反應 ICF量

Hypo: 細胞腫

Hyper: 細胞縮

就是這麼簡單

# Hyponatremia


- 第一件事先**check tonicity** 免!


1. Hypertonic hyponatremia :  
tonicity $\uparrow$  eg. Mannitol, glucose $\uparrow$

2. Isotonic hyponatremia: 假性, eg. Lipid $\uparrow$ ,  
protein $\uparrow$  (MM)

3. **Hypotonic hyponatremia**: 真的低血鈉 ,  
再往下 approach







甲、固醇、水腦

心肝腎

腦: reset, ADH



Excess H<sub>2</sub>O relative to Na, usually due to ↑ ADH

↑ ADH may be appropriate (eg, hypovolemia or hypervolemia with ↓ EAV)

↑ ADH may be **inappropriate (SIADH)**



## **Hypovolemic hypotonic hyponatremia**

(ie, ↓↓ total body Na, ↓ TBW)

Renal losses: esp. **thiazides**

Extrarenal losses: GI loss (diarrhea or vomiting),  
third-spacing (pancreatitis)

**Euvolemic hypotonic hyponatremia**(ie, ↑ TBW  
relative to total body Na

## **SIADH**

Endocrinopathies: glucocorticoid deficiency/  
**hypothyroidism**/myxedema coma





# **SIADH: 3C+藥物-CNS用藥** **過度分泌ADH**

**C**ancer: **Lung (SCLC)**, GI, pancreas, lymphoma

**C**M: Pneumonia, abscess, TB,  
Aspergillosis, Resp failure, PEEP

**C**NS: Brain tumor, abscess, meningitis, encephalitis,  
trauma, SAH

**D**rug: **clorpropamide**, clofibrate, **narcotic**, **anti-  
psychi**, carbamazepine (Tegretol), **vincristine**,  
nicotine,



# SIADH特色: euvolemic!!!!

$FE_{\text{UricAcid}}$  as  $>12\%$  suggests SIADH

$U_{\text{Na}}$  is usually above 40 mEq/L

$[K^+]$  is normal /no acid-base disturbance

[Uric acid] is frequently low



18. 下列有關低血鈉症 ( hyponatremia ) 的描述，何者正確？

(A) 如果血漿滲透壓 ( osmolality ) 偏低，應考慮是否有高血糖

**(B) 心臟衰竭可能造成細胞外體液 ( extracellular fluid ) 增加及低血鈉**

(C) 低血鈉及細胞外體液減少的病人，若尿液鈉離子濃度低於10 mmol/L，代表有Na<sup>+</sup> wasting nephropathy

(D) 抗利尿激素不適當分泌 ( SIADH ) 的病人通常血漿滲透壓正常，但細胞外體液減少



104-37

ADH:抗利尿—就是吸水！

抗利尿激素( anti-diuretic hormone ) 不適當分泌症候群 (SIADH) ， 會造成下列何種電解質異常？

- A.高鈉血症
- **B.低鈉血症**
- C.高鉀血症
- D.低鉀血症



105-34

- 下列何種引起低血鈉的情況，最適合以注射0.9%生理食鹽水來治療？
- A. 高血糖 ( hyperglycemia )
- B. 甲狀腺機能低下 ( hypothyroidism )
- **C. 皮質醛酮素缺乏 ( aldosterone deficiency )**
- D. SIADH ( syndrome of inappropriate ADH secretion )

要supple Na，最好是真的缺鈉



22 有關抗利尿激素分泌不當症候群 ( syndrome of inappropriate secretion of ADH ) 的敘述，下列何者錯誤？

(A) 診斷必須排除腎上腺或甲狀腺功能不足

(B) 通常是某些疾病的併發症，如肺結核、肺癌等

(C) 病人出現低鈉血症，是由於體液過多所致

**(C) 病人出現低鈉血症，是由於體液過多所致**

**(D) 病人的尿液鈉濃度通常大於 10 mmol/L，且滲透壓大於 100 mOsm/kgH<sub>2</sub>O**



# Hyponatremia: therapy

Acute sx: initial rapid correction of [Na]serum (**2 mEq/L/h** for the first 2–3 h) until sx resolve

Asx or chronic symptomatic:  **$\leq 0.5$  mEq/L/h**

Rate  $\uparrow$  Na should not **exceed 6 (chronic) to 8 (acute) mEq/L/d**

Complication: **CPM/ODS**: paraplegia, dysarthria, dysphagia



Hypovolemic hyponatremia:

volume repletion with **isotonic 0.9% saline**

SIADH: **fluid restrict** + treat underlying

**hypertonic saline** ± loop diuretic: for sx

**NaCl tabs or urea** if chronic and no CHF

aquaresis: vaptans

Demeclocycline: causes nephrogenic DI, ↓ Uosm (rarely used)

Hypervolemic hyponatremia: free water restrict

w/ loop diuretics (avoid thiazide)

vasodilators to ↑ CO in CHF, colloid infusion in cirrhosis





一位56歲的男性病人因半夜發生端坐呼吸至急診就診，理學檢查發現血壓為164/98 mmHg，**不規則心跳120/min**，兩側肺部**有囉音**，心尖部有III/VI之全收縮期雜音及S3奔馬音，抽血檢查**Na<sup>+</sup>: 120 mEq/L**，K<sup>+</sup>: 4.5 mEq/L，Cl<sup>-</sup>: 92 mEq/L。下列何種處置**最不適當**？

- A. 再驗其尿中Na<sup>+</sup>濃度以釐清病因
- B. 立即給予靜脈滴注3% saline以矯正其血中[Na<sup>+</sup>]**
- C. 立即給予靜脈注射furosemide
- D. 立即給予靜脈注射digoxin

99-11: hypervolemic hypoNa → diuretics



下列有關抗利尿激素不當分泌症候群

( syndrome of inappropriate antidiuretic hormone secretion, SIADH ) 的敘述，何者錯誤？

1. 為體液量低下之低血鈉 hypovolemic hyponatremia

2. 血清滲透度 ( osmolality ) 低下

3. 常合併血清低尿酸值

4. 不適當之濃縮尿液，尿液滲透度 ( urine osmolality ) 常大於 100 mosmol/kgH<sub>2</sub>O




Hypernatremia是指濃度高

Excess Na relative to H<sub>2</sub>O

就是這麼簡單

**Hypernatremia**



# Cause of hyperNa

## Hypovolemic hypernatremia

## Water loss

- Renal H<sub>2</sub>O losses ( $U_{osm}$  300-600): loop diuretics, osmotic diuresis (glc, mannitol, urea)
- Extrarenal H<sub>2</sub>O losses ( $U_{osm}$  >600): diarrhea, insensible loss (fever, exercise)

## Euvolemic hypernatremia

- Diabetes insipidus ( $U_{osm}$  <300-600): ADH defic. (central) or resist. (nephrogenic)
  - Central: congenital, trauma/surgery, tumors, or infiltrative disease of hypothalamus or posterior pituitary; also idiopathic, hypoxic encephalopathy, anorexia
  - Nephrogenic (*Annals* 2006;144:186)
    - congenital
    - drugs: Li, amphotericin, demeclocycline, foscarnet, cidofovir
    - metabolic: hypercalcemia, severe hypokalemia, protein malnutrition, congenital
    - tubulointerstitial: postobstruction, recovery phase of ATN, PKD, sickle cell, Sjögren's, amyloid, pregnancy
- DI usually presents as severe polyuria and mild hypernatremia
- Seizures, exercise ( $U_{osm}$  >600): ↑ intracellular osmoles → H<sub>2</sub>O shifts → transient ↑ [Na]<sub>serum</sub>

## Hypervolemic hypernatremia

## Excess Na

- Hypertonic saline administration: eg, cardiac arrest resuscitation with NaHCO<sub>3</sub>
- Mineralocorticoid excess: usually mild hypernatremia caused by ADH suppression

$$\text{Free H}_2\text{O deficit (L)} = \frac{[\text{Na}]_{\text{serum}} - 140}{140} \times \text{TBW}$$

TBW = wt (kg) × 0.6 (♂) or 0.5 (♀);  
if elderly use 0.5 (♂) or 0.45 (♀)

Rate of correction depends on acuity of onset and risk:  
**chronic (>48 hr): ~12 mEq/d** appears safe w/o risk of  
**cerebral edema**

**acute (<48 hr): may ↓ Na by 2 mEq/L/h** until Na 145  
hyperacute (min-hrs) & life threatening (ICH, seizure):  
rapidly infuse D5W ± emergent HD



2. 一位35歲的男性，因為意識不清被家人送至急診就醫，抽血檢查發現血鈉過高(160 mEq/L，參考值135 ~ 145 mEq/L)。有關高血鈉(hyponatremia)的處理，下列描述何者最適當？

A. 估算全身水量(total-body water)：女性是體重的60%，而男性是體重的50%

B. 此病患若體重70公斤，計算free water缺乏量(free-water deficit)約5000 c.c.

C. 不易感知的水分流失(insensible losses)約5 mL/kg/day

**D. 血鈉的矯正儘量不超過10 mM/day，以避免腦部水腫(cerebral edema)**

108年第一次專 醫學(三)  $70 \times 0.6 \times (160 - 140) / 140 = 6L$



# Polyuria >3L/day

## Definition and pathophysiology

- Polyuria defined as **>3 L UOP per day**
- Due to an *osmotic* or a *water diuresis*; almost always due to osmotic diuresis in inpatients

## Workup

- Perform a timed urine collection (6 h sufficient) and measure  $U_{osm}$
- 24-h osmole excretion rate = 24-h UOP (actual or estimate)  $\times U_{osm}$ 
  - >1000 mOsm/d  $\rightarrow$  osmotic diuresis**
  - <800 mOsm/d  $\rightarrow$  water diuresis**

## Osmotic diuresis

- Etiologies
  - Glucose (uncontrolled diabetes mellitus)
  - Mannitol
  - Urea: recovering ARF,  $\uparrow$  protein feeds, hypercatabolism (burns, steroids), GI bleed
  - NaCl administration
- Treatment: address underlying cause, replace free-water deficit and ongoing losses


## Water diuresis

- Etiologies: DI ( $Na_{serum} >140$ ) or  $1^\circ$  polydipsia ( $Na_{serum} <140$ )  
see "Hypernatremia" above for list of causes of central and nephrogenic DI
- **Workup of DI:  $U_{osm} <300$  (complete) or 300-600 (partial)**  
water deprivation test: deprive until  $P_{osm} >295$  and  $U_{osm} <300$ , then administer vasopressin (5U SC) or dDAVP (10  $\mu$ g intranasal):
  - $U_{osm} \uparrow$  by  $>50\%$  = central DI**
  - $U_{osm}$  unchanged = nephrogenic DI**
- Treatment of DI: see "Hypernatremia" above



## **Euvolemic hypernatremia**


- **Diabetes insipidus** ( $U_{osm} < 300-600$ ): ADH defic. (central) or resist. (nephrogenic)
    - Central**: congenital, trauma/surgery, tumors, or infiltrative disease of hypothalamus or posterior pituitary; also idiopathic, hypoxic encephalopathy, anorexia
    - Nephrogenic** (*Annals* 2006;144:186)
      - congenital
      - drugs: Li, amphotericin, demeclocycline, foscarnet, cidofovir
      - metabolic: hypercalcemia, severe hypokalemia, protein malnutrition, congenital
      - tubulointerstitial: postobstruction, recovery phase of ATN, PKD, sickle cell, Sjögren's, amyloid, pregnancy
- DI usually presents as *severe polyuria* and *mild hypernatremia*



**PASSED**

## Treatment

- **1° polydipsia:** treat psychiatric illness, check meds, restrict access to free H<sub>2</sub>O
- **Osmotic diuresis:** address underlying cause, replace free H<sub>2</sub>O deficit (see “Hypernatremia” for formula to calculate) and ongoing losses
- **DI:**
  - Central DI: desmopressin (dDAVP, 1<sup>st</sup> line), low Na/protein diet + HCTZ, chlorpropamide
  - Nephrogenic DI: treat underlying cause if possible; Na restriction + HCTZ (mild volume depletion → ↓ delivery of filtrate for free H<sub>2</sub>O absorption), consider amiloride for Li-induced DI (*Kid Int* 2009;76:44), indomethacin (*NEJM* 1991;324:850) or trial desmopression
  - Pregnancy-induced DI: due to vasopressinase from placenta, ∴ Rx w/ dDAVP



一位 21 歲男性因多尿及夜尿多年至門診就診，血液檢查發現：鈉 158 mmol/L，鉀 3.7 mmol/L，氯 124 mmol/L，尿液檢查發現鈉 12 mmol/L，鉀 6 mmol/L，肌酸酐 32 mg/dL，滲透度 60 mosm/kg H<sub>2</sub>O，desmopressin (DDAVP) 測試發現尿液滲透度上升至 500 mosm/kg H<sub>2</sub>O，下列敘述何者正確？

1. 病患為 primary polydipsia
2. 病患為腎因性尿崩症
- 3. 病患為中樞性尿崩症**
4. 病患為滲透性利尿症 ( osmotic diuresis )



下列何種利尿劑可以用來治療先天性腎性尿崩症 ( congenital nephrogenic diabetes insipidus ) 所引起之多尿症？① thiazides ② loop diuretics ③ acetazolamide ④ amiloride

A. ①②

B. ②③

C. ②④

**D. ①④**



# Potassium Homeostasis

低鉀鑑別診斷、對應治療

高鉀鑑別診斷、對應治療


EKG change

Urinalysis

Nephrolithiasis



# Acid-Base Disturbances/ Sodium and Water Homeostasis/ **Potassium Homeostasis**



表二 K<sup>+</sup> Shifting 疾病與 K<sup>+</sup> wasting 疾病臨床特徵與治療之比較

快速區分 K <sup>+</sup> Shifting 疾病與 K <sup>+</sup> wasting 疾病之要點		
	K <sup>+</sup> Shifting 疾病	K <sup>+</sup> wasting 疾病
發生時間	快速	漸進性
低血鉀原因	K <sup>+</sup> 移入細胞內	K <sup>+</sup> 流失
尿 K <sup>+</sup> 排出	低	通常高
Divalent abnormalities	少	常常
酸鹼平衡	正常	異常
急性治療	少劑量 K <sup>+</sup> 非選擇性乙型阻斷劑 <sup>#</sup>	大劑量 K <sup>+</sup> MgCl <sub>2</sub> <sup>§</sup>
慢性治療	acetazolamide* loop diuretics <sup>a</sup>	K <sup>+</sup> citrate <sup>&amp;</sup>
K <sup>+</sup> Shifting 疾病及 K <sup>+</sup> wasting 疾病之治療比較		
	K <sup>+</sup> Shifting 疾病	K <sup>+</sup> wasting 疾病
症狀恢復時的血清 K <sup>+</sup> 濃度	高	低
恢復時間	較短	通常較長
需 K <sup>+</sup> 補充劑量	較少量	較大量
矛盾性低血鉀 (%)	1/4	1/2
反彈性高血鉀 (%)	40~60	~0
矛盾性低血鉀之危險因子	嚴重交感興奮(hyperadrenergism)	低體液容量

<sup>#</sup> 對於明顯高腎上腺皮質功能症(hyperadrenergism)及對鉀治療反應不佳之病人或許有幫助

<sup>§</sup> 合併低血鎂的病人


\* 對 familial hypoKPP 病人(有 R/X Cav1.1 突變)較有幫助

<sup>a</sup> 仍須隨機分配試驗證實

<sup>&</sup> 用於合併 metabolic acidosis 之病人




# Acid-Base Disturbances/ Sodium and Water Homeostasis/ **Potassium Homeostasis**





# Renin-angiotensin-aldosterone- ENaC system



renin

ACE

# Hyper-RAAS

Angiotensinogen → angiotensin I → angiotensin II → aldosterone



其他來源高起來的~cortisol  
濃度太高，會作用在  
aldosterone receptor

## Suspect Hyperaldosteronism

Plasma renin & aldosterone a.m. collection

↓ renin  
↓ aldosterone

↓ renin  
**↑ aldo (>15)**  
aldo:renin >20

**↑ renin**  
↑ aldosterone  
aldo:renin ≤10

**Captopril test 確診**

Non-aldosterone  
mineralocorticoid excess

**salt suppression test**

2° Hyperaldosteronism

AME

Cushing's syndrome  
CAH (some forms)  
11β-OHSD deficiency  
甘草 Licorice (chronic ingestion)  
Liddle's syndrome  
Exogenous mineralocorticoids

slide47

1° Hyperaldosteronism

Renovascular disease  
CHF, cirrhosis, nephrotic  
Hypovolemia & diuretic use

**Barter's syndrome**  
**Gitelman's syndrome**  
Renin-secreting tumor

Volume 少

Adrenal CT or MRI

lesion no lesion

Adenoma  
Carcinoma

localize adrenal vein  
sampling

no localization

Hyperplasia  
or GRA


**11βHSD-2**

Cortisol → Cortisone  
11βHSD-1

會去作用到 **aldosterone receptor**

# Glucocorticoid remediable hyperaldosteronism (GRA)

- **Chimeric gene** : aldosterone synthase 被 11 $\beta$  hydroxylase 控制，一直製造 **aldosterone**
- Steroid 可以抑制 11 $\beta$  hydroxylase，故用 steroid CYP11B2 $\leftarrow$  CYP11B1 $\leftarrow$



# Liddle's syndrome

• 99-24 下列關於 Liddle's syndrome 的敘述，何者錯誤？

1. 為自體顯性遺傳，amiloride-sensitive sodium channel 發生 activating mutations
2. 臨床表現有高血壓，低血鉀及代謝性鹼中毒
- 3. 血清 renin 濃度高，aldosterone 濃度高**
4. 低鈉飲食及 amiloride 可矯正其高血壓及電解質異常



46 下列那一項檢查結果最符合Primary aldosteronism的診斷？

A. 尿液pH值偏酸性

B. 血鉀濃度增加

**C. 舒張性高血壓 ( diastolic hypertension ) ， 但無水腫**

D. 站立時，腎素 ( renin ) 的分泌增加



治療下列引起低血鉀之疾病，何者較容易產生反彈性高血鉀（ rebound hyperkalemia ）？

1. 低血鉀週期性無力症（ **hypokalemic periodic paralysis** ）

2. Liddle's 症候群（ Liddle's syndrome ）


3. 糖尿病酮酸血症（ diabetic ketoacidosis ）

4. 腹瀉（ diarrhea ）


95-20:反彈，表示不是真的loss,為shift而已




# Acid-Base Disturbances/ Sodium and Water Homeostasis/ **Potassium Homeostasis**



**Upper GI:**  
 **$uNa/ uCl > 1.6$**




**lower GI**  
 **$uNa/ uCl < 0.7$**






**ECG Changes with Potassium Imbalance**



**Treatment** (*JAMA* 2000;160:2429)

- If true potassium deficit: **potassium repletion** ( $\downarrow$  1 mEq/L  $\approx$  200 mEq total body loss)  
Dosage: 40 mEq PO q4h, 10 mEq/h (IV), 20 mEq/h (central line), 40 mEq in 1L IVF
- Replete  $K^+$  to  $>3$  or  $>4$  mEq/L if high-risk (HTN, CHF, arrhythmias, MI, digoxin, cirrhosis)
- Beware of excessive potassium repletion if transcellular shift cause of hypokalemia
- Treat underlying cause (if  $\downarrow$  vol: avoid dextrose as  $\uparrow$  insulin  $\rightarrow$  intracellular potassium shifts)
- Consider Rx that  $\downarrow$  K loss: ACEI/ARB,  $K^+$ -sparing diuretics,  $\beta$ B
- Replete Mg if  $<2$  mEq/L: IV  $Mg-SO_4$  1–2 g q2h (oral Mg-oxide poorly tolerated b/c diarrhea)  
Causes of low Mg: GI loss (diarrhea, bypass, pancreatitis, malnutrition, PPI); renal loss (diuretics, nephrotoxic drugs, EtOH,  $\uparrow$  Ca, 1° wasting syndromes, volume expansion)



**ECG EKG Changes in Hypokalemia and Hyperkalemia**



Therapy of Hyperkalemia	
<b>Stabilization of the Membrane</b>	
<b>IV calcium</b>	Works within min; action lasts up to 1 hr Ca gluconate 3 amp (3 g, 10% 30 mL, 14 mEq Ca) via peripheral line or CaCl <sub>2</sub> 1 amp (1 g, 10% 10 mL, 13.6 mEq Ca) via central line over 2–3 min Avoid in digitalis toxicity
<b>Drive Extracellular Potassium into the Cells</b>	
<b>Insulin + glucose</b>	Bolus 5–10 units of insulin R + 50 mL of 50% dextrose Effect starts in 10–20 min, peaks at 30–60 min, lasts for 4–6 hr K drops 0.5–1.2 mEq/L
<b>Albuterol</b>	Lowers the serum potassium concentration by 0.5–1.5 mEq/L 10–20 mg nebulizer; peak effect in 90 min Used as adjuvant to insulin + glucose
<b>Sodium bicarbonate</b>	Beneficial mainly in metabolic acidosis in acute ↑ K; and in chronic ↑ K in CKD 150 mEq in 1 L of 5% dextrose in water
<b>Removal of Potassium from the Body</b>	
<b>Diuretics</b>	Can be used for both acute and chronic hyperkalemia Dosage depends on the renal function
<b>GI cations exchangers</b>	Patiromer ( <i>NEJM</i> 2015;372:211) 8.4–25.2 g qd; give 3–6 hr after or before other po meds Exchanges K for Ca in the colon s/e: constipation, ↓ Mg Sodium zirconium cyclosilicate ( <i>NEJM</i> 2015;372:222) Sodium polystyrene sulfonate (SPS) 15–60 g single dose po (+/- sorbitol); 50 g enema (without sorbitol) Avoid in postop, ileus or bowel obstruction (s/e: intestinal necrosis)
<b>Dialysis</b>	HD is more efficacious in K removal than PD CRRT can be used subsequently in patients with ongoing K release Dialysate K <2 a/w sudden cardiac arrest ( <i>KI</i> 2011;79:218) Rebound ↑ K: K shift to serum after HD. More pronounced after albuterol, insulin and high Na <sup>+</sup> dialysate ( <i>JASN</i> 2000;11:2337), post-HD ↓ K should not be corrected unless clinically indicated




一位59歲接受腹膜透析腎病患者，血壓為125/80 mmHg，心跳為76次/min，12導程心電圖發現有 peaked T waves，血鉀值為7.0 mmol/L，無溶血。下列何種處置最不優先？



6. 一位82歲男性，有高血壓與慢性腎臟疾病，主訴最近疲倦無力，血壓152/90 mmHg，呼吸15次/分，心跳65 次/分，體溫36.5°C，心電圖顯示如下圖，其最可能為何種電解質異常？

- A. 高血鈣症(hypercalcemia)    B. 低血鈣症(hypocalcemia) )  
**C. 高血鉀症(hyperkalemia) )**    D. 低血鉀症(hypokalemia) )



血鉀異常: 人名 syndrome 大彙整

## 低血鉀 + HTN

Liddle syndrome: ENaC  $\uparrow$

Conn's syndrome: primary hyperaldo

## 低血鉀 + normal BP

Bartter / Gitelman: two diuretics

## 高血鉀 + HTN

Gordon syndrome ( $\leftrightarrow$  Gitelman)

# Renal Failure/ other electrolyte

AKI 鑑別診斷、對應治療

Potassium Homeostasis

CKD 分期/ ESRD 及治療

Renal Failure/ other electrolyte

Glomerular Disease

Urinalysis

Nephrolithiasis



## Renal Failure/ other electrolyte


AKI Staging (KDIGO AKI 2012)		
Stage	Creatinine	Urine Output (UOP)
1	↑ 0.3 in 48 hr or ↑ to 1.5–1.99x baseline w/i 7 d	<0.5 cc/kg/hr for >6–12 hr
2	↑ to 2.0–2.99x baseline w/i 7 d	<0.5 cc/kg/hr for ≥12 hr
3	↑ to ≥3x baseline w/i 7 d; OR increase in Cr to ≥4.0; OR need for RRT	<0.3 cc/kg/hr for ≥24 hr or anuria for ≥12 hr

**Table 29.5 Urine Indices Used in the Differential Diagnosis of Prerenal Acute Kidney Injury and Acute Tubular Necrosis**


Diagnostic Index	Prerenal AKI	ATN
Fractional excretion of sodium (%)	<1 <sup>a</sup>	>2 <sup>a</sup>
Urine sodium concentration (mmol/L)	<20	>40
Urine creatinine-to-plasma creatinine ratio	>40	<20
Urine urea nitrogen-to-plasma urea nitrogen ratio	>8	<3
Urine specific gravity	>1.018	~1.010
Urine osmolality (mOsm/kg H <sub>2</sub> O)	>500	~300
Plasma BUN-to-creatinine ratio	>20	<10-15
Renal failure index, $U_{Na}/(U_{Cr}/P_{Cr})$	<1	>1
Urine sediment	Hyaline casts	Muddy brown granular casts

<sup>a</sup>FE<sub>Na</sub> may be >1% in prerenal AKI associated with diuretic use and/or the setting of bicarbonaturia or chronic kidney disease; FE<sub>Na</sub> often <1% in acute tubular necrosis caused by radiocontrast or rhabdomyolysis.

AKI, Acute kidney injury; ATN, acute tubular necrosis; BUN, blood urea nitrogen; P<sub>Cr</sub>, plasma creatinine; U<sub>Cr</sub>, urine creatinine; U<sub>Na</sub>, urine sodium.



# KDIGO慢性腎臟病分期



持續白蛋白尿的分期

A1 正常到 輕度升高 <30 mg/g <3 mg/mmol	A2 中度升高 30-300 mg/g 3-30 mg/mmol	A3 重度升高 >300 mg/g >30 mg/mmol
Green	Yellow	Orange
Green	Yellow	Orange
Yellow	Orange	Red
Orange	Red	Red
Red	Red	Red
Red	Red	Red

綠色：低風險；黃色（中度風險）；橙色（高風險）；紅色（非常高的風險）

資料來源：恩主公醫院腎臟科張嘉峯醫師





22. 72歲男性為慢性腎病病人，血中肌酸酐 (creatinine ) 6.3 mg/dL，下列何種酸鹼電解質狀態最少發生在此病人？

**A. 鈉( $\text{Na}^+$ ) 148 mEq/L**

B. 鉀( $\text{K}^+$ ) 5.6 mEq/L

C. 磷( $\text{PO}_4^{3-}$ ) 5.5 mg/dL

D. 鈣( $\text{Ca}^{2+}$ ) 8.0 mg/dL



65歲女性病人因長期糖尿病腎病變，接受規則血液透析治療已5年，透析前血中磷(  $\text{PO}_4^{3-}$  ) 6.8 mg/dL、鈣(  $\text{Ca}^{++}$  ) 10.8 mg/dL、副甲狀腺賀爾蒙( PTH ) 88 pg/mL。對此病人，下列何者為最適當治療？

**A.使用磷結合劑( phosphate binder )**

B.使用維他命D3( vitamin D3 )

C.使用擬鈣劑( calcimimetic )

D.使用鈣濃度3.0 mEq/L透析液

